

# the **ADBL** report

Issue #106, February 2019

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross  
The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

#### EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC, (Chair)  
Fiona Clement, PhD, (Vice-Chair)  
Caitlin Clarke, BScPhm, PharmD  
Margaret Gray, BSP, FCSHP  
Mike Kolber, BSc, MD, CCFP, MSc  
Naeem Ladhani, BScPharm  
Tony Nickonchuk, BScPharm  
Glen J. Pearson, BScPhm, PharmD, FCSHP, FCCS  
Jeremy Slobodan, BSP  
Donna Woloschuk, BSP, PharmD, M.Ed. FCSHP

#### ALBERTA HEALTH LIAISON:

Chad Mitchell, BSc Pharm, MSc

#### ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)  
Amanda Chung, BSc (Pharm)  
Sherry Dieleman, BSc (Pharm), MSc  
Connie Lussier, BSP, MA

## In this issue:

- **Brief Summary of Drug Review Activities**
- **Highlights of:**
  - ❖ **Products Originally Reviewed via the Common Drug Review (CDR)**
  - ❖ **Drug Products Added**
  - ❖ **Expedited Interchangeable (IC) Drug Products Added**
  - ❖ **Interchangeable (IC) Drug Products Added**
- **Step Therapy/Special Authorization Criteria Changes**

## Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on November 22 and 23, 2018. The Committee reviewed Manufacturer submissions for thirty-four (34) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of twenty-four (24) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, forty-four (44) Drug Products underwent Expedited Review for listing on the ADBL effective December 1, 2018 and twelve (12) Drug Products underwent Expedited Review for listing on the ADBL effective February 1, 2019.

The following are **highlights** of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.html>

## Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the ADBL effective December 1, 2018:

- **ACTIKERALL** (5-fluorouracil/salicylic acid) (CIP) **0.5%/10% topical solution**
- **BRIVLERA\*** (brivaracetam) (UCB) **10 mg, 25 mg, 50 mg, 75 mg & 100 mg tablets** via Special Authorization (SA)
- **DYSPORT THERAPEUTIC** (abobotulinumtoxinA) (ISP) **300 IU/vial & 500 IU/vial injections**
- **ENSTILAR** (calcipotriol monohydrate/betamethasone dipropionate) (LEO) **50 mcg/g/0.5 mg/g topical foam**
- **HEMANGIOL\*** (propranolol hydrochloride) (PIE) **3.75 mg/mL oral solution** via SA
- **LANCORA\*** (ivabradine hydrochloride) (SEV) **5 mg & 7.5 mg tablets** via SA
- **QUINSAIR\*** (levofloxacin) (RAP) **100 mg/mL inhalation solution** via Step Therapy/SA
- **SPINRAZA\*** (nusinersen sodium) (BIO) **2.4 mg/mL injection** via SA
- **TRESIBA FLEXTOUCH PEN** (insulin degludec) (NNA) **100 unit/mL & 200 unit/mL injections**

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).\*

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective January 1, 2019:

- **OCALIVA\*** (obeticholic acid) (ICP) **5 mg & 10 mg tablets** via SA
- **RENFLEXIS\*** (infliximab) (SSB) **100 mg/vial injection** via SA
- **REVESTIVE\*** (teduglutide) (SHB) **5 mg/vial injection** via SA
- **SYNJARDY\*** (empagliflozin/metformin hydrochloride) (BOE) **5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg & 12.5 mg/1000 mg tablets** via Step Therapy/SA

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via SA effective February 1, 2019:

- **MDK-NITISINONE\*** (nitisinone) (MEN) **2 mg, 5 mg & 10 mg capsules**
- **NITISINONE\*** (nitisinone) (CYC) **2 mg, 5 mg & 10 mg tablets**
- **ORFADIN\*** (nitisinone) (BVM) **2 mg, 5 mg, 10 mg & 20 mg capsules**
- **PRALUENT\*** (alirocumab) (SAV) **75 mg/mL & 150 mg/mL injection pens & syringes**

## *Highlights of Drug Products Added*

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective February 1, 2019:

- **CAMPRAL\*** (acamprosate calcium) (MVP) **333 mg delayed-release tablet** via SA
- **MEZERA** (mesalazine) (AVP) **1 g rectal suppository**

## *Highlights of Expedited Interchangeable (IC) Drug Products Added*

Addition of the following Expedited Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective December 1, 2018:

- **APO-HYDROMORPHONE CR** (hydromorphone hydrochloride) (APX) **3 mg, 4.5 mg, 6 mg, 9 mg, 18 mg, 24 mg & 30 mg controlled release capsules**

- **LACOSAMIDE\*** (lacosamide) (various brands: AUR, PMS, SDZ, TEV) **50 mg, 100 mg, 150 mg & 200 mg tablets** listed via SA
- **MAR-METHIMAZOLE** (thiamazole) (MAR) **5 mg tablet**

Addition of the following Expedited Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective February 1, 2019:

- **TARO-DIPYRIDAMOLE/ ASA** (dipyridamole/acetylsalicylic acid) (TAR) **200 mg/25 mg capsule**

## *Highlights of Interchangeable (IC) Drug Products Added*

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of a New IC Grouping, effective February 1, 2019:

- **APO-HYDROMORPHONE CR** (hydromorphone hydrochloride) (APX) **12 mg controlled-release capsule**
- **APO-NALTREXONE** (naltrexone hydrochloride) (APX) **50 mg tablet**
- **APO-PINAVERIUM** (pinaverium bromide) (APX) **50 mg & 100 mg tablets**
- **BACKUP PLAN ONESTEP** (levonorgestrel) (APX) **1.5 mg tablet**
- **NALTREXONE HYDROCHLORIDE TABLETS USP** (naltrexone hydrochloride) (JPC) **50 mg tablet**

## *Step Therapy/Special Authorization Criteria Changes*

The Step Therapy/Special Authorization criteria for coverage for the following Drug Product has been revised effective December 1, 2018:

- **CAYSTON\*** (aztreonam) (GIL) **75 mg/vial powder for inhalation solution**

The Step Therapy/Special Authorization criteria for coverage for the following Drug Products have been revised effective January 1, 2019:

- **JARDIANCE\*** (empagliflozin) (BOE) **10 mg & 25 mg tablets**

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*